Posted inDiabetes & Endocrinology news Rheumatology
Can an 11β‑HSD1 Inhibitor Improve Prednisolone’s Benefit–Risk Ratio in Polymyalgia Rheumatica? Early Human Trial Suggests Feasibility
A single‑blind sequential cohort trial found that clofutriben, a selective 11β‑HSD1 inhibitor, reduced biomarkers of glucocorticoid toxicity while partially attenuating prednisolone efficacy at low doses; efficacy was restored at higher prednisolone doses, supporting further randomized trials.
